CG
LVTX

Cutler Group’s LAVA Therapeutics LVTX Stock Holding History

Cutler Group’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$3K Buy
+1,000
New +$2.2K ﹤0.01% 1730

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cutler Group's LVTX Position: Q1 2024 in Review

Cutler Group opened a new position in LAVA Therapeutics (LVTX) in Q1 2024: 1,000 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #1730 among its holdings.

20 funds tracked by Wall St. Rank hold LVTX as of Q1 2024.

  • Cutler Group held 1,000 shares of LAVA Therapeutics worth $3K as of Q1 2024.
  • LAVA Therapeutics was a new Cutler Group position in Q1 2024.
  • LAVA Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1730 holding.
  • 20 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.